關於減重藥物與保險給付的最新消息
New updates on weight loss medications and insurance access
Updated at: June 12, 2026 at 01:15 AM
截至2026年中，減重藥物的現況經歷了巨大的轉變，同時伴隨著新機遇與持續存在的挑戰。
As of mid-2026, the landscape for weight loss medication has undergone a significant transformation, marked by both new opportunities and persistent challenges.
2026年7月1日是一個重要的里程碑，當天「聯邦醫療保險GLP-1過渡計畫」正式啟動。
A major milestone arrived on July 1, 2026, with the launch of the Medicare GLP-1 Bridge Program.
這項臨時倡議使聯邦醫療保險D部分的受保人，能以每月50美元的固定自付額使用Wegovy和Zepbound等藥物，並在2027年底前繞過標準的福利門檻。
This temporary initiative allows Medicare Part D beneficiaries to access medications like Wegovy and Zepbound with a fixed $50 monthly copayment, bypassing standard benefit hurdles through the end of 2027.
許多雇主正在實施更嚴格的事前授權要求或「分階治療」——即要求患者先嘗試較便宜的治療方案——以控制日益增長的成本。
Many employers are implementing stricter prior authorization requirements or 'step therapy'—mandating that patients try cheaper treatments first—to control rising costs.
藥物獲取管道極度分散，承保範圍往往與嚴格的身體質量指數(BMI)標準掛鉤，並隨州別與雇主的不同而有極大差異。
Access is highly fragmented, with coverage often tied to strict BMI criteria and varying widely by state and employer.
由於成本居高不下，許多患者轉向現金支付方式或數位健康平台。
As costs remain high, many patients are turning to cash-pay options or digital health platforms.
雖然聯邦醫療保險過渡計畫提供了一條重要的生命線，但對全國許多人來說，能持續且穩定地取得這些藥物仍是一場持續的鬥爭。
While the Medicare Bridge program offers a vital lifeline, sustainable and consistent access to these medications remains an ongoing struggle for many across the country.
